Cite
HARVARD Citation
Reijers, . et al. (n.d.). 6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma. Immuno-oncology technology. p. . [Online].